12 January 2020
IntegraGen announced today its unaudited business figures for the year 2019.
2019 revenue amounted to 8.3 M € versus 6.9 M € in 2018, an increase of 20% over 12 months. This performance highlights an acceleration from the high growth level of 15% reported for the first half of 2019. (…) »
23 September 2019
IntegraGen has announced today its financial results for the first half of 2019 with the accounts having been reviewed by the Board of Directors on 19 September 2019.
Sales: 4.2 M€, up + 15% vs. H1 2018 Operating profit (EBITDA): -0.3 M€, up + 31% vs. H1 2018
30 June 2019
The mixed shareholders’ general meeting of IntegraGen was held on Thursday, June 13, 2019 at the Bedford Hotel’s premises at 17 rue de l’Arcade in Paris.
At the end of the Combined General Meeting, (…) »
18 April 2019
IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019.
Click here to view press release.
15 March 2019
Come and meet us at the #ConfMidCap2019 @Portzamparc, April 10th!
05 March 2019
IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.
09 January 2019
IntegraGen announced today its unaudited annual sales revenue for 2018.
Sales revenue of €6.9 million (+11%) Very strong increase (+29%) in sequencing services for the R&D segment Strong reduction in cash consumption. Cash position of €4.0 million as of December 31, 2018 Commercial launch of SIRIUS and MERCURY online genomic data (…) »
12 November 2018
IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools. (…) »
21 October 2018
Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy
IntegraGen announced today that it presented data on the company’s proprietary miR-31 (…) »
20 September 2018
IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.
Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57% vs. (…) »